Current Concepts in Refractory Migraine Authors
HEADACHE (JR COUCH, SECTION EDITOR)
First Online: 13 November 2012 DOI:
Cite this article as: Schulman, E. & McGeeney, B.E. Curr Treat Options Neurol (2013) 15: 40. doi:10.1007/s11940-012-0206-5 Opinion statement
The Refractory or Intractable Migraine (RM) patient has long been a challenge to all healthcare providers (HCP). Headache specialists have recognized this sub group of patients who remain refractory to treatment. Despite this recognition, there are no formal criteria that characterize RM. This article will attempt to provide treatment approaches, some scientifically based and others that are empiric. A reasonable goal is to lessen disability. Combining the various modalities will improve the chances for successful treatment. The foundation of treatment is an emphasis on wellness. This includes optimizing mood, minimizing stress, practicing good sleep hygiene, and avoiding triggers. All comorbid factors should be addressed, including sleep and mood disorders, chronic neck pain, and obesity. Preventive treatment is necessary in the majority of patients, and a plan for “rescue” approaches is essential. Avoiding medication overuse, particularly narcotics, is advisable. Additional options for treatment include onabotulinumtoxinA, and more invasive modalities, such as neurostimulation. Adjunct treatment including supplements and relaxation may also be considered. Keeping a headache calendar is almost mandatory in management with attention to particular headache triggers, patterns and medication overuse (MOH). A trusting physician–patient relationship is also very important and will enhance compliance and foster communication. Patients often lapse from the management plan and the treating physician should be open minded about continuing care. RM is a long-term disease and requires close physician–patient interaction and cooperation for management of the problem. In those RM patients with multiple comorbidities, a multidisciplinary team should optimize management.
Keywords Refractory Migraine Intractable Classification Definition Neurostimulation Supplements Sleep disorders Depression Anxiety Risk factors Abortive Prophylaxis Dopamine antagonists Opioids Anticonvulsants Nerve blocks Treatment References and Recommended Readings Papers of particular interest, published recently, have been highlighted as: • Of importance
Goadsby P, Schoenen J, Ferrari M, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168–70.
Schulman EA, Lake III AE, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache J Head Face Pain. 2008;48:778–82.
Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache J Head Face Pain. 2010;50:1499–506.
Robbins L. Refractory headache definition. Headache J Head Face Pain. 2011;51:310–1.
Robbins L. Refractory chronic migraine: long-term follow-up using a refractory rating scale. J Headache Pain. 2012;13:225–9.
Schulman EA, Lipton R, Peterlin BL, et al. Commentary from the refractory headache special interest section on defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache J Head Face Pain. 2010;50:1637–9.
Irimia P, Palma JA, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol. 2011;11:94.
Busch V, Gaul C. Exercise in migraine therapy–is there any evidence for efficacy? A critical review. Headache. 2008;48:890–9.
Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334–43.
Lipton R, Diamond M, Freitag F, et al. Migraine prevention patterns in a community sample: Results from the American Migraine Prevalence and Prevention (AMPP) study. Philadelphia: American Headache Society 47th Annual Scientific Meeting; 2005.
Loder E, Biondi D. General principles of migraine management: The changing role of prevention. Headache. 2005;45:S33–47.
Evans RW, Williams MA, Rapoport AM, Peterlin BL. The association of obesity with episodic and chronic migraine. Headache. 2012;52:663–71.
Peterlin BL. Bariatric surgery in obese migraineurs: Mounting evidence but important questions remain. Cephalalgia. 2011;31:1333–5.
Andress-Rothrock D, King W, Rothrock J. An analysis of migraine triggers in a clinic-based population. Headache. 2010;50:1366–70.
Sauro KM, Becker WJ. The stress and migraine interaction. Headache. 2009;49:1378–86.
Dodick DW, Eross EJ, Parish JM, Silber M. Clinical, anatomical, and physiologic relationship between sleep and headache. Headache. 2003;43:282–92.
Rains JC. Chronic headache and potentially modifiable risk factors: Screening and behavioral management of sleep disorders. Headache. 2008;48:32–9.
Rains JC, Poceta JS. Headache and sleep disorders: Review and clinical implications for headache management. Headache. 2006;46:1344–63.
Rains JC, Poceta JS. Sleep and headache. Curr Treat Options Neurol. 2010;12:1–15. A comprehensive review of sleep and how it applies to headache.
Sancisi E, Cevoli S, Vignatelli L, et al. Increased prevalence of sleep disorders in chronic headache: A case–control study. Headache. 2010;50:1464–72.
Griffiths R, Evans S, Heishman S, et al. Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther. 1990;255:1123–32.
Cripe SM, Sanchez SE, Gelaye B, et al. Association between intimate partner violence, migraine and probable migraine. Headache J Head Face Pain. 2011;51:208–19.
Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: A multicenter headache clinic survey. Headache. 2009;50:20–31.
Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. Headache. 2009;50:32–41.
Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part III). Association with comorbid pain conditions. Headache. 2009;50:42–51.
McGeeney BE. Acute and urgent treatment of refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010. p. 116–35.A more comprehensive review of acute treatment in the refractory migraine patient.
Mathew NT. Prophylactic treatment of refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. 1st ed. New York: Oxford University Press; 2010. p. 101–15. A more comprehensie review of prophylactic treatment in the refractory migraine patient.
Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: Naproxen sodium v ergotamine plus caffeine. Headache J Head Face Pain. 1988;28:263–6.
Silberstein SD, Freitag FG, Bigal ME. Migraine treatment. In: Silberstein S, Lipton RB, Dodick DE, editors. Wolf's headache and other head pain. 8th ed. New York: Oxford University Press; 2008. p. 177–292.
Scott AK. Dihydroergotamine: A review of its Use in the treatment of migraine and other headaches. Clin Neuropharmacol. 1992;15:289–96.
Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7.
McGeeney BE. Dopamine antagonists and migraine. Drug Dev Res. 2007;68:341–5.
Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA J Am Med Assoc. 1989;261:1174–6.
Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359–61.
Ziegler DK. Opioids in headache treatment: Is there a role? Neurol Clin. 1997;15:199–207.
Saper JR, Lake AE, Bain PA, et al. A practice guide for continuous opioid therapy for refractory daily headache: Patient selection, physician requirements, and treatment monitoring. Headache J Head Face Pain. 2010;50:1175–93.
Diener H, Bussone G, Oene JCV, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.
Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacother. 2007;8:2811–23.
Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: Randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44–8.
Holland S, Silberstein S, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.
Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–4.
Ashkenazi A, Levin M. Nerve blocks, neurostimulation, and botulinum toxin injection treatment for refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. 1st ed. New York: Oxford University Press; 2010. p. 266–92.Excellent practical chapter on the nerve blocks for headache.
Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes–prolonged effects from a single injection. Pain. 2006;122:126–9.
Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.
Diener H, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.
Lambru G, Matharu MS. Occipital nerve stimulation in primary headache syndromes. Ther Adv Neurol Disord. 2012;5:57–67.
Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 2012;11:708–19.
Saper JR, Lake III AE. Inpatient strategies for refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine: Mechanisms and management. New York: Oxford University Press; 2010. p. 341.This chapter, written by an expert in the field, provides an excellent overview of treating RM.
Schulman EA. Historical overview of refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. 1st ed. New York: Oxford University Press; 2010. p. 5–18.
© Springer Science+Business Media New York 2012